Pier 88 Investment Partners’s Pyxis Oncology PYXS Stock Holding History

Pier 88 Investment Partners’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-151,730	Closed	-$337K	–	123
2025 Q3	$337K	Sell	151,730 -215,440	-59%	-$310K	0.06%	105
2025 Q2	$404K	Sell	367,170 -23,790	-6%	-$26.8K	0.08%	93
2025 Q1	$383K	Buy	390,960 +292,370	+297%	+$390K	0.07%	91
2024 Q4	$154K	Sell	98,590 -23,020	-19%	-$66.4K	0.03%	90
2024 Q3	$446K	Buy	121,610 +7,910	+7%	+$27.7K	0.1%	76
2024 Q2	$376K	Buy	113,700 +62,340	+121%	+$262K	0.08%	87
2024 Q1	$219K	Buy	+51,360	New	+$216K	0.05%	87

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pier 88 Investment Partners's PYXS Position: Q4 2025 in Review

Pier 88 Investment Partners sold out of Pyxis Oncology (PYXS) in Q4 2025, closing a stake of 151,730 shares — an estimated $337K sold.

Pier 88 Investment Partners first reported a position in PYXS in Q1 2024 and held it in 7 quarters. The position peaked at $446K in Q3 2024. 79 funds tracked by Wall St. Rank hold PYXS as of Q4 2025.

Pier 88 Investment Partners reported no remaining Pyxis Oncology position as of Q4 2025 after selling out during the quarter.
Pier 88 Investment Partners sold 151,730 Pyxis Oncology shares in Q4 2025, an estimated $337K.
Pier 88 Investment Partners first reported a position in Pyxis Oncology in Q1 2024 and held it in 7 quarters.
Pier 88 Investment Partners's Pyxis Oncology position peaked at $446K in Q3 2024.
79 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2025.

Based on Pier 88 Investment Partners's 13F filing for Q4 2025, filed 4 Feb 2026.